This site is intended for health professionals only

Home / News / Recall: Patients advised to return Emerade 500 micrograms adrenaline pens to pharmacies

Recall: Patients advised to return Emerade 500 micrograms adrenaline pens to pharmacies

By Isabel Shaw

19 May 2020

Allergy patients who carry an Emerade 500 microgram adrenaline auto-injector pen are being advised to return the pens to their pharmacies after a fault was discovered.

The advice from the Medicines and Healthcare products Regulatory Agency (MHRA) (May 18), stated that some of the pens are faulty and do not activate properly. This means that the correct dose of adrenaline required by a patient suffering a severe allergic reaction may not be delivered.

Pharmacists and other healthcare professionals have been asked by the MHRA to ‘contact patients who use Emerade 500 microgram pens’ and ask them to ‘request a new prescription from their prescriber to replace each Emerade 500mcg auto-injector with new 300mcg adrenaline auto-injectors in an alternative brand.’

They should also tell these patients or their carers to return their Emerade 500 microgram auto-injectors to the pharmacy once they have sourced two alternative adrenaline auto-injectors in a different brand.

‘There is evidence to suggest that a single EpiPen 300mcg or Jext 300mcg pen will be a suitable replacement for a single Emerade 500mcg pen,’ the MHRA advised.

The MHRA has recalled the pens in three separate phases spread over the last two months to ‘ensure there would be enough supplies of alternative pens’.

Want news like this straight to your inbox?

Latest News

Free PPE for pharmacy teams extended for a further year
Community pharmacies in England will be eligible to receive free personal protective equipment (PPE) from...
boosters pharmacy
One-third of all boosters delivered by pharmacies
Pharmacy-led vaccine sites across England have delivered one-third of all booster vaccines, as more sites...
registration assessment provider
GPhC announces new common registration assessment provider
The General Pharmaceutical Council (GPhC) has appointed a new provider to run the common registration...